Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBP) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Regen BioPharma (RGBP) over the last 12 years, with Q3 2025 value amounting to 0.05%.

  • Regen BioPharma's Return on Capital Employed fell 300.0% to 0.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.05%, marking a year-over-year decrease of 300.0%. This contributed to the annual value of 0.05% for FY2025, which is 300.0% down from last year.
  • As of Q3 2025, Regen BioPharma's Return on Capital Employed stood at 0.05%, which was down 300.0% from 0.05% recorded in Q2 2025.
  • Over the past 5 years, Regen BioPharma's Return on Capital Employed peaked at 0.15% during Q2 2023, and registered a low of 0.0% during Q1 2022.
  • For the 5-year period, Regen BioPharma's Return on Capital Employed averaged around 0.07%, with its median value being 0.06% (2024).
  • Examining YoY changes over the last 5 years, Regen BioPharma's Return on Capital Employed showed a top increase of 1400bps in 2023 and a maximum decrease of -800bps in 2023.
  • Quarter analysis of 5 years shows Regen BioPharma's Return on Capital Employed stood at 0.03% in 2021, then surged by 377bps to 0.14% in 2022, then crashed by -52bps to 0.07% in 2023, then dropped by -10bps to 0.06% in 2024, then dropped by -14bps to 0.05% in 2025.
  • Its Return on Capital Employed was 0.05% in Q3 2025, compared to 0.05% in Q2 2025 and 0.06% in Q1 2025.